Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06476847 · ClinicalTrials.gov registry record · NA

A Simple Intervention to Increase Persistence on PrEP in MSM to Improve Decision Making

A NA study of HIV Infections, sponsored by Boston University.

Active
Registry status
NA
Development phase
106
Enrollment target
2
Study locations

NCT06476847: Active NA study of HIV Infections, sponsored by Boston University.

NCT06476847 is a NA study of HIV Infections that is active but no longer recruiting, run by Boston University. The registered enrollment target is 106 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06476847, a NA study of HIV Infections, is active but no longer recruiting, sponsored by Boston University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
106 participants
Enrollment target
2
Study locations

Study Summary

Oral HIV pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention modality that requires individuals to take a daily tablet to prevent themselves acquiring HIV. In South Africa while this is freely available in the public sector, persistence (that is continuation after initiation) is low amongst vulnerable populations, including men who have sex with men (MSM). This study is a feasibility and acceptability study of a behavioral economics informed intervention to improve persistence amongst MSM newly initiating PrEP in South Africa. The goal of this study is to show that this approach is possible in a routine setting and gather the necessary data for a fully powered effectiveness trial. Study participants will complete a baseline questionnaire and then be randomized to either receive standard of care (control) or to receive the intervention. The intervention package consists of evidence informed reminders, commitment pledges and planning prompts. The intervention package aims to address present bias, optimism bias and salience. The intervention is delivered and the enrollment visit and then through mobile phone reminders / text messages. There is no further in person interaction after the initial interaction. Participants may be contacted for a telephonic enplane questionnaire. Outcome data is obtained from passive followup through routine medical record review with the primary end point being persistence at 3 months.

Primary Outcome

The percent of participants enrolled from those that meet eligibility criteria and are offered will be assessed from screening log.

Conditions Studied

Interventions

  • BEHAVIORAL PrEP persistence

Study Locations (2)

Massachusetts

  • Boston Univeristy School ofPublic Health, Global Health - Boston

Gauteng

  • The Aurum POP INN Clinic - Pretoria

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2025-01-23
Est. Completion 2026-09
Phase NA
Boston University

185 total trials

What the registry record for NCT06476847 still lists

NCT06476847 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (76% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which PrEP persistence is the first listed.

NCT06476847 reports a single indexed study location in Massachusetts, Gauteng.

Frequently Asked Questions

What is clinical trial NCT06476847 about?

NCT06476847 is a clinical study titled "A Simple Intervention to Increase Persistence on PrEP in MSM to Improve Decision Making". Oral HIV pre-exposure prophylaxis (PrEP) is a highly effective HIV prevention modality that requires individuals to take a daily tablet to prevent themselves acquiring HIV. In South Africa while this is freely available in the public sector, persistence (that is continuation after initiation) is low...

What is the current status of trial NCT06476847?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 106 participants. The study started on 2025-01-23. Estimated completion is 2026-09.

What conditions does trial NCT06476847 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT06476847?

The interventions under investigation include: PrEP persistence (BEHAVIORAL).

Who is sponsoring clinical trial NCT06476847?

This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06476847 being conducted?

This trial has 2 study locations across Massachusetts, Gauteng. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06476847's enrollment target sits among peer trials

106 257th of 542 higher than 285 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03181048 · 106 participants · NA

    Clinical Trial of Concomitant Hip Arthroscopy During PAO

  • NCT04682158 · 106 participants · Phase 2

    Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

  • NCT04724018 · 106 participants · Phase 1

    Sacituzumab Govitecan Plus EV in Metastatic UC

  • NCT04798274 · 106 participants · NA

    Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06476847, the US trial registry maintained by the National Library of Medicine. NCT06476847 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.